Back to School: How biopharma can reboot drug development. Access exclusive analysis here

J&J, Schering-Plough deal

Johnson & Johnson's Centocor Inc. subsidiary and Schering-Plough revised a 1998 deal, giving Schering-Plough exclusive rights to market Remicade infliximab and golimumab

Read the full 225 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE